Global and United States Antidiabetic SGLT-2 Inhibitor Market Report & Forecast 2022-2028

Global and United States Antidiabetic SGLT-2 Inhibitor Market Report & Forecast 2022-2028

Table of Contents
1 Study Coverage
1.1 Antidiabetic SGLT-2 Inhibitor Product Introduction
1.2 Global Antidiabetic SGLT-2 Inhibitor Outlook 2017 VS 2022 VS 2028
1.2.1 Global Antidiabetic SGLT-2 Inhibitor Sales in US$ Million for the Year 2017-2028
1.2.2 Global Antidiabetic SGLT-2 Inhibitor Sales in Volume for the Year 2017-2028
1.3 United States Antidiabetic SGLT-2 Inhibitor Outlook 2017 VS 2022 VS 2028
1.3.1 United States Antidiabetic SGLT-2 Inhibitor Sales in US$ Million for the Year 2017-2028
1.3.2 United States Antidiabetic SGLT-2 Inhibitor Sales in Volume for the Year 2017-2028
1.4 Antidiabetic SGLT-2 Inhibitor Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Antidiabetic SGLT-2 Inhibitor in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Antidiabetic SGLT-2 Inhibitor Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Antidiabetic SGLT-2 Inhibitor Market Dynamics
1.5.1 Antidiabetic SGLT-2 Inhibitor Industry Trends
1.5.2 Antidiabetic SGLT-2 Inhibitor Market Drivers
1.5.3 Antidiabetic SGLT-2 Inhibitor Market Challenges
1.5.4 Antidiabetic SGLT-2 Inhibitor Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Antidiabetic SGLT-2 Inhibitor Market Segment by Type
2.1.1 Canagliflozin
2.1.2 Empagliflozin
2.1.3 Dapagliflozin
2.1.4 Other
2.2 Global Antidiabetic SGLT-2 Inhibitor Market Size by Type
2.2.1 Global Antidiabetic SGLT-2 Inhibitor Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Antidiabetic SGLT-2 Inhibitor Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Antidiabetic SGLT-2 Inhibitor Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Antidiabetic SGLT-2 Inhibitor Market Size by Type
2.3.1 United States Antidiabetic SGLT-2 Inhibitor Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Antidiabetic SGLT-2 Inhibitor Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Antidiabetic SGLT-2 Inhibitor Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Antidiabetic SGLT-2 Inhibitor Market Segment by Application
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Other
3.2 Global Antidiabetic SGLT-2 Inhibitor Market Size by Application
3.2.1 Global Antidiabetic SGLT-2 Inhibitor Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Antidiabetic SGLT-2 Inhibitor Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Antidiabetic SGLT-2 Inhibitor Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Antidiabetic SGLT-2 Inhibitor Market Size by Application
3.3.1 United States Antidiabetic SGLT-2 Inhibitor Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Antidiabetic SGLT-2 Inhibitor Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Antidiabetic SGLT-2 Inhibitor Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Antidiabetic SGLT-2 Inhibitor Competitor Landscape by Company
4.1 Global Antidiabetic SGLT-2 Inhibitor Market Size by Company
4.1.1 Top Global Antidiabetic SGLT-2 Inhibitor Manufacturers Ranked by Revenue (2021)
4.1.2 Global Antidiabetic SGLT-2 Inhibitor Revenue by Manufacturer (2017-2022)
4.1.3 Global Antidiabetic SGLT-2 Inhibitor Sales by Manufacturer (2017-2022)
4.1.4 Global Antidiabetic SGLT-2 Inhibitor Price by Manufacturer (2017-2022)
4.2 Global Antidiabetic SGLT-2 Inhibitor Concentration Ratio (CR)
4.2.1 Antidiabetic SGLT-2 Inhibitor Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Antidiabetic SGLT-2 Inhibitor in 2021
4.2.3 Global Antidiabetic SGLT-2 Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Antidiabetic SGLT-2 Inhibitor Manufacturing Base Distribution, Product Type
4.3.1 Global Antidiabetic SGLT-2 Inhibitor Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Antidiabetic SGLT-2 Inhibitor Product Type
4.3.3 Date of International Manufacturers Enter into Antidiabetic SGLT-2 Inhibitor Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Antidiabetic SGLT-2 Inhibitor Market Size by Company
4.5.1 Top Antidiabetic SGLT-2 Inhibitor Players in United States, Ranked by Revenue (2021)
4.5.2 United States Antidiabetic SGLT-2 Inhibitor Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Antidiabetic SGLT-2 Inhibitor Sales by Players (2020, 2021 & 2022)
5 Global Antidiabetic SGLT-2 Inhibitor Market Size by Region
5.1 Global Antidiabetic SGLT-2 Inhibitor Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Antidiabetic SGLT-2 Inhibitor Market Size in Volume by Region (2017-2028)
5.2.1 Global Antidiabetic SGLT-2 Inhibitor Sales in Volume by Region: 2017-2022
5.2.2 Global Antidiabetic SGLT-2 Inhibitor Sales in Volume Forecast by Region (2023-2028)
5.3 Global Antidiabetic SGLT-2 Inhibitor Market Size in Value by Region (2017-2028)
5.3.1 Global Antidiabetic SGLT-2 Inhibitor Sales in Value by Region: 2017-2022
5.3.2 Global Antidiabetic SGLT-2 Inhibitor Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Antidiabetic SGLT-2 Inhibitor Market Size YoY Growth 2017-2028
6.1.2 North America Antidiabetic SGLT-2 Inhibitor Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 China Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.3 Europe
6.3.1 Europe Antidiabetic SGLT-2 Inhibitor Market Size YoY Growth 2017-2028
6.3.2 Europe Antidiabetic SGLT-2 Inhibitor Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Antidiabetic SGLT-2 Inhibitor Market Size YoY Growth 2017-2028
6.4.2 Latin America Antidiabetic SGLT-2 Inhibitor Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 UAE
7 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Corporation Information
7.1.2 Pfizer Description and Business Overview
7.1.3 Pfizer Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Pfizer Antidiabetic SGLT-2 Inhibitor Products Offered
7.1.5 Pfizer Recent Development
7.2 AstraZeneca
7.2.1 AstraZeneca Corporation Information
7.2.2 AstraZeneca Description and Business Overview
7.2.3 AstraZeneca Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
7.2.4 AstraZeneca Antidiabetic SGLT-2 Inhibitor Products Offered
7.2.5 AstraZeneca Recent Development
7.3 Johnson & Johnson
7.3.1 Johnson & Johnson Corporation Information
7.3.2 Johnson & Johnson Description and Business Overview
7.3.3 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Products Offered
7.3.5 Johnson & Johnson Recent Development
7.4 GlaxoSmithKline
7.4.1 GlaxoSmithKline Corporation Information
7.4.2 GlaxoSmithKline Description and Business Overview
7.4.3 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
7.4.4 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Products Offered
7.4.5 GlaxoSmithKline Recent Development
7.5 Merck & Co
7.5.1 Merck & Co Corporation Information
7.5.2 Merck & Co Description and Business Overview
7.5.3 Merck & Co Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Merck & Co Antidiabetic SGLT-2 Inhibitor Products Offered
7.5.5 Merck & Co Recent Development
7.6 Eli Lilly
7.6.1 Eli Lilly Corporation Information
7.6.2 Eli Lilly Description and Business Overview
7.6.3 Eli Lilly Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Eli Lilly Antidiabetic SGLT-2 Inhibitor Products Offered
7.6.5 Eli Lilly Recent Development
7.7 Sanofi
7.7.1 Sanofi Corporation Information
7.7.2 Sanofi Description and Business Overview
7.7.3 Sanofi Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Sanofi Antidiabetic SGLT-2 Inhibitor Products Offered
7.7.5 Sanofi Recent Development
7.8 Takeda Pharmaceuticals
7.8.1 Takeda Pharmaceuticals Corporation Information
7.8.2 Takeda Pharmaceuticals Description and Business Overview
7.8.3 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Products Offered
7.8.5 Takeda Pharmaceuticals Recent Development
7.9 Novo Nordisk
7.9.1 Novo Nordisk Corporation Information
7.9.2 Novo Nordisk Description and Business Overview
7.9.3 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Products Offered
7.9.5 Novo Nordisk Recent Development
7.10 Servier Laboratories
7.10.1 Servier Laboratories Corporation Information
7.10.2 Servier Laboratories Description and Business Overview
7.10.3 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Products Offered
7.10.5 Servier Laboratories Recent Development
7.11 Boehringer Ingelheim
7.11.1 Boehringer Ingelheim Corporation Information
7.11.2 Boehringer Ingelheim Description and Business Overview
7.11.3 Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
7.11.4 Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Products Offered
7.11.5 Boehringer Ingelheim Recent Development
7.12 Bristol-Myers Squibb
7.12.1 Bristol-Myers Squibb Corporation Information
7.12.2 Bristol-Myers Squibb Description and Business Overview
7.12.3 Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Bristol-Myers Squibb Products Offered
7.12.5 Bristol-Myers Squibb Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Antidiabetic SGLT-2 Inhibitor Industry Chain Analysis
8.2 Antidiabetic SGLT-2 Inhibitor Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Antidiabetic SGLT-2 Inhibitor Distributors
8.3 Antidiabetic SGLT-2 Inhibitor Production Mode & Process
8.4 Antidiabetic SGLT-2 Inhibitor Sales and Marketing
8.4.1 Antidiabetic SGLT-2 Inhibitor Sales Channels
8.4.2 Antidiabetic SGLT-2 Inhibitor Distributors
8.5 Antidiabetic SGLT-2 Inhibitor Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Antidiabetic SGLT-2 Inhibitor CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
Table 2. Antidiabetic SGLT-2 Inhibitor Market Trends
Table 3. Antidiabetic SGLT-2 Inhibitor Market Drivers
Table 4. Antidiabetic SGLT-2 Inhibitor Market Challenges
Table 5. Antidiabetic SGLT-2 Inhibitor Market Restraints
Table 6. Global Antidiabetic SGLT-2 Inhibitor Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Antidiabetic SGLT-2 Inhibitor Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Antidiabetic SGLT-2 Inhibitor Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Antidiabetic SGLT-2 Inhibitor Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Antidiabetic SGLT-2 Inhibitor Manufacturers in Global Market, Ranking by Revenue (2021)
Table 11. Global Antidiabetic SGLT-2 Inhibitor Revenue by Manufacturer, (US$ Million), 2017-2022
Table 12. Global Antidiabetic SGLT-2 Inhibitor Revenue Share by Manufacturer, 2017-2022
Table 13. Global Antidiabetic SGLT-2 Inhibitor Sales by Manufacturer, (K Pcs), 2017-2022
Table 14. Global Antidiabetic SGLT-2 Inhibitor Sales Share by Manufacturer, 2017-2022
Table 15. Global Antidiabetic SGLT-2 Inhibitor Price by Manufacturer (2017-2022) & (USD/Pcs)
Table 16. Global Antidiabetic SGLT-2 Inhibitor Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Antidiabetic SGLT-2 Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antidiabetic SGLT-2 Inhibitor as of 2021)
Table 18. Top Players of Antidiabetic SGLT-2 Inhibitor in Global Market, Headquarters and Distribution of Producing Region
Table 19. Manufacturers Antidiabetic SGLT-2 Inhibitor Product Type
Table 20. Date of International Manufacturers Enter into Antidiabetic SGLT-2 Inhibitor Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Top Antidiabetic SGLT-2 Inhibitor Players in United States Market, Ranking by Revenue (2021)
Table 23. United States Antidiabetic SGLT-2 Inhibitor Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 24. United States Antidiabetic SGLT-2 Inhibitor Revenue Share by Players, 2020, 2021 & 2022
Table 25. United States Antidiabetic SGLT-2 Inhibitor Sales by Players, (K Pcs), 2020, 2021 & 2022
Table 26. United States Antidiabetic SGLT-2 Inhibitor Sales Share by Players, 2020, 2021 & 2022
Table 27. Global Antidiabetic SGLT-2 Inhibitor Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 28. Global Antidiabetic SGLT-2 Inhibitor Sales in Volume by Region (2017-2022) & (K Pcs)
Table 29. Global Antidiabetic SGLT-2 Inhibitor Sales in Volume Forecast by Region (2023-2028) & (K Pcs)
Table 30. Global Antidiabetic SGLT-2 Inhibitor Sales in Value by Region (2017-2022) & (US$ Million)
Table 31. Global Antidiabetic SGLT-2 Inhibitor Sales in Value Forecast by Region (2023-2028) & (US$ Million)
Table 32. North America Antidiabetic SGLT-2 Inhibitor Sales in Volume by Country (2017-2028) & (K Pcs)
Table 33. North America Antidiabetic SGLT-2 Inhibitor Sales in Value by Country (2017-2028) & (US$ Million)
Table 34. Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales in Volume by Region (2017-2028) & (K Pcs)
Table 35. Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales in Value by Region (2017-2028) & (US$ Million)
Table 36. Europe Antidiabetic SGLT-2 Inhibitor Sales in Volume by Country (2017-2028) & (K Pcs)
Table 37. Europe Antidiabetic SGLT-2 Inhibitor Sales in Value by Country (2017-2028) & (US$ Million)
Table 38. Latin America Antidiabetic SGLT-2 Inhibitor Sales in Volume by Country (2017-2028) & (K Pcs)
Table 39. Latin Americaa Antidiabetic SGLT-2 Inhibitor Sales in Value by Country (2017-2028) & (US$ Million)
Table 40. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales in Volume by Country (2017-2028) & (K Pcs)
Table 41. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales in Value by Country (2017-2028) & (US$ Million)
Table 42. Pfizer Corporation Information
Table 43. Pfizer Description and Business Overview
Table 44. Pfizer Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 45. Pfizer Antidiabetic SGLT-2 Inhibitor Product
Table 46. Pfizer Recent Development
Table 47. AstraZeneca Corporation Information
Table 48. AstraZeneca Description and Business Overview
Table 49. AstraZeneca Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 50. AstraZeneca Product
Table 51. AstraZeneca Recent Development
Table 52. Johnson & Johnson Corporation Information
Table 53. Johnson & Johnson Description and Business Overview
Table 54. Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 55. Johnson & Johnson Product
Table 56. Johnson & Johnson Recent Development
Table 57. GlaxoSmithKline Corporation Information
Table 58. GlaxoSmithKline Description and Business Overview
Table 59. GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 60. GlaxoSmithKline Product
Table 61. GlaxoSmithKline Recent Development
Table 62. Merck & Co Corporation Information
Table 63. Merck & Co Description and Business Overview
Table 64. Merck & Co Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 65. Merck & Co Product
Table 66. Merck & Co Recent Development
Table 67. Eli Lilly Corporation Information
Table 68. Eli Lilly Description and Business Overview
Table 69. Eli Lilly Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 70. Eli Lilly Product
Table 71. Eli Lilly Recent Development
Table 72. Sanofi Corporation Information
Table 73. Sanofi Description and Business Overview
Table 74. Sanofi Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 75. Sanofi Product
Table 76. Sanofi Recent Development
Table 77. Takeda Pharmaceuticals Corporation Information
Table 78. Takeda Pharmaceuticals Description and Business Overview
Table 79. Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 80. Takeda Pharmaceuticals Product
Table 81. Takeda Pharmaceuticals Recent Development
Table 82. Novo Nordisk Corporation Information
Table 83. Novo Nordisk Description and Business Overview
Table 84. Novo Nordisk Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 85. Novo Nordisk Product
Table 86. Novo Nordisk Recent Development
Table 87. Servier Laboratories Corporation Information
Table 88. Servier Laboratories Description and Business Overview
Table 89. Servier Laboratories Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 90. Servier Laboratories Product
Table 91. Servier Laboratories Recent Development
Table 92. Boehringer Ingelheim Corporation Information
Table 93. Boehringer Ingelheim Description and Business Overview
Table 94. Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 95. Boehringer Ingelheim Product
Table 96. Boehringer Ingelheim Recent Development
Table 97. Bristol-Myers Squibb Corporation Information
Table 98. Bristol-Myers Squibb Description and Business Overview
Table 99. Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 100. Bristol-Myers Squibb Product
Table 101. Bristol-Myers Squibb Recent Development
Table 102. Key Raw Materials Lists
Table 103. Raw Materials Key Suppliers Lists
Table 104. Antidiabetic SGLT-2 Inhibitor Customers List
Table 105. Antidiabetic SGLT-2 Inhibitor Distributors List
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
List of Figures
Figure 1. Antidiabetic SGLT-2 Inhibitor Product Picture
Figure 2. Global Antidiabetic SGLT-2 Inhibitor Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Antidiabetic SGLT-2 Inhibitor Market Size 2017-2028 (US$ Million)
Figure 4. Global Antidiabetic SGLT-2 Inhibitor Sales 2017-2028 (K Pcs)
Figure 5. United States Antidiabetic SGLT-2 Inhibitor Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 6. United States Antidiabetic SGLT-2 Inhibitor Market Size 2017-2028 (US$ Million)
Figure 7. United States Antidiabetic SGLT-2 Inhibitor Sales 2017-2028 (K Pcs)
Figure 8. United States Antidiabetic SGLT-2 Inhibitor Market Share in Global, in Value (US$ Million) 2017-2028
Figure 9. United States Antidiabetic SGLT-2 Inhibitor Market Share in Global, in Volume (K Pcs) 2017-2028
Figure 10. Antidiabetic SGLT-2 Inhibitor Report Years Considered
Figure 11. Product Picture of Canagliflozin
Figure 12. Product Picture of Empagliflozin
Figure 13. Product Picture of Dapagliflozin
Figure 14. Product Picture of Other
Figure 15. Global Antidiabetic SGLT-2 Inhibitor Market Share by Type in 2022 & 2028
Figure 16. Global Antidiabetic SGLT-2 Inhibitor Sales in Value by Type (2017-2028) & (US$ Million)
Figure 17. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Type (2017-2028)
Figure 18. Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2017-2028) & (K Pcs)
Figure 19. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Type (2017-2028)
Figure 20. Global Antidiabetic SGLT-2 Inhibitor Price by Type (2017-2028) & (USD/Pcs)
Figure 21. United States Antidiabetic SGLT-2 Inhibitor Market Share by Type in 2022 & 2028
Figure 22. United States Antidiabetic SGLT-2 Inhibitor Sales in Value by Type (2017-2028) & (US$ Million)
Figure 23. United States Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Type (2017-2028)
Figure 24. United States Antidiabetic SGLT-2 Inhibitor Sales by Type (2017-2028) & (K Pcs)
Figure 25. United States Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Type (2017-2028)
Figure 26. United States Antidiabetic SGLT-2 Inhibitor Price by Type (2017-2028) & (USD/Pcs)
Figure 27. Product Picture of Hospitals
Figure 28. Product Picture of Clinics
Figure 29. Product Picture of Other
Figure 30. Global Antidiabetic SGLT-2 Inhibitor Market Share by Application in 2022 & 2028
Figure 31. Global Antidiabetic SGLT-2 Inhibitor Sales in Value by Application (2017-2028) & (US$ Million)
Figure 32. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Application (2017-2028)
Figure 33. Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2017-2028) & (K Pcs)
Figure 34. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Application (2017-2028)
Figure 35. Global Antidiabetic SGLT-2 Inhibitor Price by Application (2017-2028) & (USD/Pcs)
Figure 36. United States Antidiabetic SGLT-2 Inhibitor Market Share by Application in 2022 & 2028
Figure 37. United States Antidiabetic SGLT-2 Inhibitor Sales in Value by Application (2017-2028) & (US$ Million)
Figure 38. United States Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Application (2017-2028)
Figure 39. United States Antidiabetic SGLT-2 Inhibitor Sales by Application (2017-2028) & (K Pcs)
Figure 40. United States Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Application (2017-2028)
Figure 41. United States Antidiabetic SGLT-2 Inhibitor Price by Application (2017-2028) & (USD/Pcs)
Figure 42. North America Antidiabetic SGLT-2 Inhibitor Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 43. North America Antidiabetic SGLT-2 Inhibitor Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 44. U.S. Antidiabetic SGLT-2 Inhibitor Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 45. Canada Antidiabetic SGLT-2 Inhibitor Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 46. Europe Antidiabetic SGLT-2 Inhibitor Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 47. Europe Antidiabetic SGLT-2 Inhibitor Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 48. Germany Antidiabetic SGLT-2 Inhibitor Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 49. France Antidiabetic SGLT-2 Inhibitor Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 50. U.K. Antidiabetic SGLT-2 Inhibitor Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 51. Italy Antidiabetic SGLT-2 Inhibitor Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 52. Russia Antidiabetic SGLT-2 Inhibitor Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 53. Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 54. Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 55. China Antidiabetic SGLT-2 Inhibitor Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 56. Japan Antidiabetic SGLT-2 Inhibitor Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 57. South Korea Antidiabetic SGLT-2 Inhibitor Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 58. India Antidiabetic SGLT-2 Inhibitor Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 59. Australia Antidiabetic SGLT-2 Inhibitor Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 60. China Taiwan Antidiabetic SGLT-2 Inhibitor Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 61. Indonesia Antidiabetic SGLT-2 Inhibitor Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 62. Thailand Antidiabetic SGLT-2 Inhibitor Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 63. Malaysia Antidiabetic SGLT-2 Inhibitor Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 64. Latin America Antidiabetic SGLT-2 Inhibitor Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 65. Latin America Antidiabetic SGLT-2 Inhibitor Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 66. Mexico Antidiabetic SGLT-2 Inhibitor Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 67. Brazil Antidiabetic SGLT-2 Inhibitor Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 68. Argentina Antidiabetic SGLT-2 Inhibitor Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 69. Middle East & Africa Antidiabetic SGLT-2 Inhibitor Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 70. Middle East & Africa Antidiabetic SGLT-2 Inhibitor Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 71. Turkey Antidiabetic SGLT-2 Inhibitor Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 72. Saudi Arabia Antidiabetic SGLT-2 Inhibitor Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 73. UAE Antidiabetic SGLT-2 Inhibitor Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 74. Antidiabetic SGLT-2 Inhibitor Value Chain
Figure 75. Antidiabetic SGLT-2 Inhibitor Production Process
Figure 76. Channels of Distribution
Figure 77. Distributors Profiles
Figure 78. Bottom-up and Top-down Approaches for This Report
Figure 79. Data Triangulation
Figure 80. Key Executives Interviewed

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Metformin Hydrochloride Market Research Report 2024

Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 104

Metformin hydrochloride is The raw material of finished product metformin hydrochloride drugs. That is The API metformin hydrochloride. Metformin Hydrochloride finished product is an oral antihyperglycemic drug used in The management of type 2-diabetes. Metformin hydrochloride (N, N-dimethylimidodicarbonimidic diamide hydrochloride) is not chemically or pharmacologically related to any other classes of oral antihyperglycemic agents. Metformin hydrochloride is a white to off-white crystall......

Global Antidiabetic Sulphonylureas Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 112

Market Overview of Global Antidiabetic Sulphonylureas market: According to our latest research, the global Antidiabetic Sulphonylureas market looks promising in the next 5 years. As of 2022, the global Antidiabetic Sulphonylureas market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of t......

Global Insulin Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 101

According to our LPI (LP Information) latest study, the global Insulin market size was valued at US$ million in 2023. With growing demand in downstream market, the Insulin is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Insulin market. Insulin are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization......

Global Insulin API Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 116

According to our LPI (LP Information) latest study, the global Insulin API market size was valued at US$ 1707.6 million in 2023. With growing demand in downstream market, the Insulin API is forecast to a readjusted size of US$ 2101.4 million by 2030 with a CAGR of 3.0% during review period. The research report highlights the growth potential of the global Insulin API market. Insulin API are expected to show stable growth in the future market. However, product differentiation, reducing co......

Global Glucagon Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 101

According to our LPI (LP Information) latest study, the global Glucagon market size was valued at US$ 543.9 million in 2023. With growing demand in downstream market, the Glucagon is forecast to a readjusted size of US$ 835.7 million by 2030 with a CAGR of 6.3% during review period. The research report highlights the growth potential of the global Glucagon market. Glucagon are expected to show stable growth in the future market. However, product differentiation, reducing costs, and suppl......

Global Acarbose Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 95

According to our LPI (LP Information) latest study, the global Acarbose market size was valued at US$ 135.8 million in 2023. With growing demand in downstream market, the Acarbose is forecast to a readjusted size of US$ 165.9 million by 2030 with a CAGR of 2.9% during review period. The research report highlights the growth potential of the global Acarbose market. Acarbose are expected to show stable growth in the future market. However, product differentiation, reducing costs, and suppl......

Global Insulin Glargine Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 77

According to our LPI (LP Information) latest study, the global Insulin Glargine market size was valued at US$ 6562.1 million in 2023. With growing demand in downstream market, the Insulin Glargine is forecast to a readjusted size of US$ 8722.5 million by 2030 with a CAGR of 4.1% during review period. The research report highlights the growth potential of the global Insulin Glargine market. Insulin Glargine are expected to show stable growth in the future market. However, product differen......

Global Liraglutide Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 103

According to our LPI (LP Information) latest study, the global Liraglutide market size was valued at US$ million in 2023. With growing demand in downstream market, the Liraglutide is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Liraglutide market. Liraglutide are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply ch......

Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 96

According to our LPI (LP Information) latest study, the global Glucagon Like Peptide-1 (GLP-1) Agonists market size was valued at US$ 8624.4 million in 2023. With growing demand in downstream market, the Glucagon Like Peptide-1 (GLP-1) Agonists is forecast to a readjusted size of US$ 21310 million by 2030 with a CAGR of 13.8% during review period. The research report highlights the growth potential of the global Glucagon Like Peptide-1 (GLP-1) Agonists market. Glucagon Like Peptide-1 (GL......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs